Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
19 Results for "
HDAC8 PROTAC
" in MedChemExpress (MCE) Product Catalog:
Products (19)
19 Results for "HDAC8 PROTAC" in MCE Product Catalog:
1
1 Cited Publications
Cat. No.: HY-164233
CAS No.: 2742732-92-7
YX968 is a selective HDAC3/HDAC8 PROTAC dual degrader, with a DC50 value of 1.7 nM against HDAC3 and 6.1 nM against HDAC8. YX968 inhibits cancer cell growth, induces apoptosis, prevents global histone hyperacetylation, and exerts effects via antiproliferative activity. YX968 can be used in research related to triple-negative breast cancer, non-small cell lung cancer, and multiple myeloma .
Target:
Research Areas:
SZUH280 is a selective HDAC8 PROTAC degrader with a DC50 of 0.58 μM. SZUH280 recruits the CRBN E3 ubiquitin ligase to mediate polyubiquitination and proteasomal degradation of HDAC8, and exhibits higher selectivity for HDAC8 over other HDAC family members. SZUH280 induces apoptosis and G2/M cell cycle arrest in cancer cells. SZUH280 impairs DNA damage repair and promotes radiosensitization in cancer cells. SZUH280 inhibits the proliferation of cancer cells. SZUH280 is used in research related to lung cancer and breast cancer .
Cat. No.: HY-168175
PROTAC HDAC8 Degrader-2 is a HDAC6/8 PROTAC degrader, with IC50 values of 0.042 μM and 0.147 μM against human HDAC8 and HDAC6, respectively, and exhibits selectivity over other class I HDAC isozymes. PROTAC HDAC8 Degrader-2 induces apoptosis (apoptosis) in leukemia cells, shows no obvious cytotoxicity to normal cells, and has favorable chemical stability. PROTAC HDAC8 Degrader-2 can be used in research related to acute myeloid leukemia .
Cat. No.: HY-181023
PROTAC HDAC8 Degrader-3 (Compound BP1) is an efficient and selective HDAC8 PROTAC degrader with a DC50 of 20 nM. PROTAC HDAC8 Degrader-3 exhibits IC50 for HDAC8 and CRBN of 0.46 and 7.5 μM, respectively. PROTAC HDAC8 Degrader-3 exhibits potent anti-proliferative activity against MM.1S and HL-60 cells. PROTAC HDAC8 Degrader-3 can be used for research on multiple myeloma and acute myeloid leukemia .
Cat. No.: HY-181024
PROTAC HDAC8 Degrader-3 (Compound BP6) is an efficient, selective and low-toxicity HDAC8 PROTAC degrader with a DC50 of 80 nM. PROTAC HDAC8 Degrader-3 exhibits IC50 of PROTAC for HDAC8 and CRBN of 0.26 and 30 μM respectively. PROTAC HDAC8 Degrader-3 increases the level of Ac-SMC3, stabilizes p53 and sensitizes targeted reagents (such as Idasanutlin (HY-15676)), demonstrating its great potential in combination therapy .
Cat. No.: HY-189151
CAS No.: 3057302-21-0
PROTAC HDAC8 Degrader-5 is a selective HDAC8 PROTAC degrader that mediates ubiquitination and proteasomal degradation through the formation of a ternary complex. PROTAC HDAC8 Degrader-5 degrades HDAC8 with a DC50 of 1.8 nM in MDA-MB-231 cells and a DC50 of 4.7 nM in Jurkat cells. PROTAC HDAC8 Degrader-5 inhibits cancer cell migration and proliferation, induces apoptosis through caspase 3/7 activation, and increases acetylated SMC3 and α-tubulin. PROTAC HDAC8 Degrader-5 is useful for cancer-related research, such as leukemia, triple-negative breast cancer, etc. .
Cat. No.: HY-168176
Research Areas:
HDAC8 ligand 1 is a PROTAC target protein-ligand of PROTAC HDAC8 Degrader-2 (HY-168174) .
Cat. No.: HY-163921
CAS No.: 3035977-24-0
Research Areas:
HDAC8-IN-11 is a ligand for target protein for pROTAC.
Cat. No.: HY-189873
Research Areas:
HDAC8 ligand 4 is an HDAC8 ligand. HDAC8 ligand 4 can be used as a target protein ligand to synthesize HDAC8 PROTAC degraders, such as YL633 (HY-189839). HDAC8 ligand 4 can be used in research related to diffuse large B-cell lymphoma .
Cat. No.: HY-187005
Research Areas:
HDAC8 ligand 2 is a HDAC8 ligand that can be used for the synthesis of PROTACs, such as SZUH280 (HY-152147) .
Cat. No.: HY-189824
Research Areas:
HDAC8 ligand 3 is the target protein ligand of XY-09-36 (HY-189823), and XY-09-36 is a HDAC8 PROTAC degrader. HDAC8 ligand 3 can be used in research related to Ewing sarcoma .
Cat. No.: HY-189838
CAS No.: 3100238-91-0
YL246 is a selective, CRBN-recruiting HDAC8 PROTAC degrader, DC50 = 3.75 nM. YL246 induces CRBN- and proteasome-dependent degradation of zinc-dependent HDAC8 through CRBN ligand-mediated ubiquitination. YL246 has poor metabolic stability. YL246 can be used for HDAC8-mediated cancer-related research, such as breast cancer .
Cat. No.: HY-189823
CAS No.: 3025448-71-6
XY-09-36 is a HDAC8 PROTAC degrader with a DC50 value of 30 nM (HEK 293T eGFP.HDAC8-IRES-mCherry reporter cells, 24 h). XY-09-36 binds HDAC8 and recruits VHL E3 ubiquitin ligase, inducing HDAC8 ubiquitination and proteasomal degradation; the IC50 values of XY-09-36 against HDAC8 and HDAC6 are 2.03 μM and 7.21 μM, respectively. XY-09-36 selectively reduces the viability of STAG2-mutant Ewing sarcoma cells. XY-09-36 increases acetylated SMC3 levels. XY-09-36 can be used for research on Ewing sarcoma .
Cat. No.: HY-189839
CAS No.: 3100239-28-6
YL633 is a selective CRBN-recruiting HDAC8 PROTAC degrader with DC50 = 3.3 nM. YL633 binds to the CRBN E3 ubiquitin ligase and mediates HDAC8 degradation. YL633 inhibits HDAC3 enzymatic activity with IC50 of 342.9 nM, and induces degradation of HDAC6 and HDAC7. YL633 inhibits DLBCL cell proliferation. YL633 can be used in research related to diffuse large B-cell lymphoma .
Cat. No.: HY-181043
CAS No.: 3052115-00-8
Research Areas:
CRBN ligand-895-PEG2-N3 (Compound 15) is a synthetic E3 ligase linker conjugate that can be used for the synthesis of PROTACs, such as PROTAC HDAC8 Degrader-4 (HY-181024) .
Cat. No.: HY-181042
CAS No.: 2782024-56-8
Target:
Research Areas:
CRBN ligand-895 (Compound 14) is an E3 ubiquitin ligase ligand for cereblon (CRBN), which is used to recruit the cereblon protein. CRBN ligand-895 can be used for the synthesis of PROTACs, such as PROTAC HDAC8 Degrader-4 (HY-181024) .
- 1
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
